

Cancer – a growing business line

- Cancer cases at Avera McKennan have increased by 24 percent since 2002.
- The top 2 sites, lung and breast cancer, have increased 65 percent and 27 percent, respectively in the last 5 years in terms of patients treated.
- Inpatient and outpatient discharges have grown by 12.69%, with a 19.2% increase in clinic visits
- Oncology/hematology inpatient care specifically has grown by 20 percent.
- Medical Oncology clinic growth has continued at the rate of more than 20 percent annually.

Cancer cases per year at Avera McKennan are expected to increase approximately 25 percent by 2016.

Overall Stats

- According to the American Cancer Society, cancer survival is currently 66% compared to 51% in 1975.
- Looking at Avera Cancer Institute statistics, the survival rate is comparable, at around 66%.

Importance of Cancer Product Line to Avera's Business Model

- Cancer is an important part of Avera McKennan's business, representing a substantial portion of inpatient hospital profit.
- Tours of leading cancer centers have revealed that services offered at the Avera Cancer Institute already meet or exceed the services of these premier centers. The presence of a bone marrow transplant program makes the ACI even more prestigious. To not build this facility would prevent Avera Cancer Institute from expanding world-class services that are critical for our community to care for those with cancer.
- Expansion of cancer services will prepare the Avera Cancer Institute for the coming upswing in cancer cases, as the "baby boomer" population ages. For example, the new building will double the capacity to serve infusion or chemotherapy patients.
- Expansion of cancer services, including integrative therapies, will address the changing desires and needs of today's cancer patients.